Plexision
PERSONALIZED MEDICINE FOR BETTER HEALTH

Plexision
4424 Penn Avenue, Suite 202, Medical Building, Pittsburgh, PA 15224
Phone: 1(855)-753-9474 or 1(855)-PLEXISI, Fax: 412-224-2776
State ID: 32485 CLIA ID: 39D2042664

Test Report : Pleximmune™

Patient Name: **Accession Number:**

Insurance Details:

Carrier: Plan Name:

Member ID #: Group ID #:

Additional Comments, if any:

Date of Birth: **Gender:** ◯ Male ◯ Female

Sample Collection Date: **Time:** ◯ AM ◯ PM

Sample Receipt Date: **Time:** ◯ AM ◯ PM

Time from transplant: Pre-transplant ☐ **Post-transplant** ☐

Sample Condition when received:

Sodium Heparin Tube: ◯ Yes ◯ No Seal Intact: ◯ Yes ◯ No

Blood Clot: ◯ Yes ◯ No Volume: ◯ 3-5 ml ◯ Other

Recipient and donor HLA information: ◯ Yes ◯ No

Sample: ◯ Not adequate for assay ◯ Assayed

Patient HLA: HLA-A: HLA-B: HLA-DR:

Donor HLA: HLA-A: HLA-B: HLA-DR:

Physician Ordering Test: **NPI #:**

Facility:

Assay Report Date: **Time:** ◯ AM ◯ PM

Donor-induced CD154+TcM: % **Third-party-induced CD154+TcM:** %

Immunoreactivity Index (IR):

Assay interpretation: Increased/Decreased risk of rejection

Reference range: For post-transplant blood samples, an IR >= 1.1 implies increased risk. An IR < 1.1 implies decreased risk.
For pre-transplant samples, an IR >= 1.23 implies increased risk. An IR <1.23 implies decreased risk.

Interpretation: Results of this assay should be used in conjunction with medical history, clinical presentation and other clinical and laboratory indicators when establishing the risk of rejection. The risk of rejection is specific to the transplant recipient. The immunoreactivity index is a calculated numeric value. The actual value does not indicate the severity of rejection. The value only indicates increased or decreased risk of rejection based on whether it is at or above the rejection thresholds as described under reference range.

Limitation: Pleximmune™ is a Laboratory Developed Test developed by Plexision. Test results should be used as an adjunct to clinical information and laboratory results to aid in the evaluation of the immunological risk for Acute Cellular Rejection (ACR) in children with liver and small bowel transplantation. The Pleximmune™ test has neither prognostic nor diagnostic value for the evaluation of Antibody Mediated Rejection (AMR), nor Chronic Rejection. The performance of the test has not been established in the presence of viral or bacterial infections, or during the period of 61-199 days after transplantation.

Director:

Name: Signature: Date & Time: 06/13/2014 09:00 AM

SAVE FORM